Andrew L Pecora Net Worth

The estimated Net Worth of Andrew L Pecora is at least $724 ezer dollars as of 18 November 2013. Andrew Pecora owns over 50,000 units of Cancer Genetics stock worth over $10,783 and over the last 12 years Andrew sold CGIX stock worth over $713,500.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Andrew Pecora CGIX stock SEC Form 4 insiders trading

Andrew has made over 1 trades of the Cancer Genetics stock since 2013, according to the Form 4 filled with the SEC. Most recently Andrew sold 50,000 units of CGIX stock worth $713,500 on 18 November 2013.

The largest trade Andrew's ever made was selling 50,000 units of Cancer Genetics stock on 18 November 2013 worth over $713,500. On average, Andrew trades about 4,545 units every 0 days since 2013. As of 18 November 2013 Andrew still owns at least 2,391 units of Cancer Genetics stock.

You can see the complete history of Andrew Pecora stock trades at the bottom of the page.

What's Andrew Pecora's mailing address?

Andrew's mailing address filed with the SEC is C/O CALADRIUS BIOSCIENCES, INC., 106 ALLEN ROAD, BASKING RIDGE, NJ, 07920.

Insiders trading at Cancer Genetics

Over the last 12 years, insiders at Cancer Genetics have traded over $1,720,897 worth of Cancer Genetics stock and bought 3,891,559 units worth $4,573,241 . The most active insiders traders include John Pappajohn, Tommy G Thompson és John A Roberts. On average, Cancer Genetics executives and independent directors trade stock every 35 days with the average trade being worth of $340,207. The most recent stock trade was executed by John A Roberts on 31 January 2019, trading 185,436 units of CGIX stock currently worth $42,650.

What does Cancer Genetics do?

Complete history of Andrew Pecora stock trades at Caladrius Biosciences Inc és Cancer Genetics

Cancer Genetics executives and stock owners

Cancer Genetics executives and other stock owners filed with the SEC include:

• Jane Houldsworth,
  Vice President - Research & Development
• Franklyn Prendergast,
  Independent Director
• Howard McLeod,
  Independent Director
• Edmund Cannon,
  Independent Director
• Thomas Widmann,
  Director
• Geoffrey Harris,
  Director
• John Roberts,
  President, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer
• John Pappajohn,
  Non-Executive Chairman of the Board
• Panna Sharma,
  Chief Executive Officer
• Raju S.K. Chaganti,
  Director
• Michael J. Welsh,
  Director
• Edward J Sitar,
  Chief Financial Officer
• Igor Gitelman,
  Chief Accounting Officer
• Michael Brian Mc Cartney,
  Chief Commercial Officer
• Michael Glenn Miles,
  Chief Financial Officer
• Ralf Brandt,
  President, Discovery Services
• Rita Shaknovich,
  VP of Hematopathology Services
• Paul Rothman,
  Director
• Keith L Brownlie,
  Director
• Andrew L Pecora,
  Director
• Tommy G Thompson,
  Director
• Steven Hepburn,
  VP of Biopharma Marketing